8 completed. 5 Phase 2, 4 Phase 1, 1 Phase 3.
By phase and status
Follow myrcludex-B: new trials by email Literature Review of myrcludex-B trials Research Report on myrcludex-B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function Bulevirtide - Hepatic Impairment, Healthy | Phase 1 | Completed | 74 | 2023-03-15 | 2026-01-26 |
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function Bulevirtide (BLV) - Chronic Hepatitis D Infection | Phase 1 | Completed | 41 | 2023-03-15 | 2025-09-18 |
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) - Chronic Hepatitis Delta | Phase 2 | Completed | 175 | 2019-05-31 | 2024-10-08 |
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide - Chronic Hepatitis Delta | Phase 3 | Completed | 150 | 2019-04-17 | 2025-08-22 |
Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent Myrcludex B, PEG IFN alfa-2a, Tenofovir - Chronic Viral Hepatitis B With Delta-agent | Phase 2 | Completed | 90 | 2016-04-01 | 2021-04-30 |
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D Myrcludex B, Myrcludex-B, Tenofovir - Chronic Hepatitis D Infection With Hepatitis B | Phase 2 | Completed | 120 | 2016-02-16 | 2021-05-10 |
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection PEG IFN alfa-2a, Myrcludex B - Chronic Hepatitis D Infection | Phase 1 / Phase 2 | Completed | 24 | 2014-02-13 | 2018-04-13 |
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B Entecavir, Myrcludex B - Chronic Hepatitis B | Phase 1 / Phase 2 | Completed | 48 | 2012-11-14 | 2018-09-19 |
Conditions studied
Hepatitis D, Chronic (2) · Hepatitis B, Chronic (1) · Hepatitis D (1)
Sponsors
Gilead Sciences (4) · Hepatera Ltd. (4)
Countries
Russia (5) · United States (3) · Germany (2) · France (1) · Italy (1) · Moldova (1) · Romania (1) · Sweden (1)
Top investigators
Pavel Bogomolov, PhD (3) · Heiner Wedemeyer, MD,PhD (1)
Results publications
PMID 38340811, PMID 39648559, PMID 37120031, PMID 36113537, PMID 38842520, PMID 39009085, PMID 39853842, PMID 41405233, PMID 41966308
NIH funding
2019 (2)